NASDAQ:NEUP

Neuphoria Therapeutics Q3 2025 Earnings Results & Report

Neuphoria Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics beat analyst earnings expectations in its Q3 2025 results, released May 20, 2025. The company reported EPS of $6.55 versus the -$0.47 consensus estimate, while revenue was $15 million.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

Neuphoria Therapeutics EPS Results

Actual EPS
$6.55
Consensus EPS
-$0.47
Beat/Miss
Beat by +$7.02
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
$15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Q3 2025 Earnings FAQ

Neuphoria Therapeutics (NASDAQ:NEUP) reported earnings of $6.55 per share for Q3 2025, beating the consensus estimate of -$0.47. The report was announced on Tuesday, May 20, 2025.

Neuphoria Therapeutics reported revenue of $15 million for Q3 2025.

Neuphoria Therapeutics Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions.

The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies.

Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

View Neuphoria Therapeutics Profile